导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.68% | 2711/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -4.07% | 2191/5421 |
| 近一季 | -7.15% | 2309/5209 |
| 近半年 | -2.52% | 1930/4920 |
| 近一年 | 0.45% | 2564/4366 |
| 近两年 | 43.63% | 1701/2954 |
| 近三年 | 25.64% | 1249/2253 |
| 成立以来 | 65.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.66% 3341/4961 |
12.04% 2245/5312 |
- - |
- - |
| 2025 | 18.55% 2304/4813 |
-1.13% 2587/3635 |
1.98% 1971/4076 |
17.76% 2442/4524 |
-0.16% 2391/4813 |
| 2024 | 16.11% 848/3463 |
2.75% 717/2808 |
-1.10% 935/3014 |
16.44% 1457/3129 |
-1.86% 1870/3463 |
| 2023 | -9.08% 1100/2656 |
4.33% 979/2280 |
-3.88% 944/2385 |
-2.82% 757/2515 |
-6.70% 1882/2655 |
| 2022 | -19.17% 812/2207 |
-13.89% 866/1919 |
6.94% 570/2016 |
-13.71% 951/2113 |
1.71% 1170/2208 |
| 2021 | -2.59% 860/1822 |
-2.83% 714/1255 |
4.49% 880/1330 |
-5.42% 804/1466 |
1.44% 935/1822 |
| 2020 | 32.39% 485/1250 |
-9.38% 671/1028 |
13.44% 618/1067 |
13.80% 309/1164 |
13.15% 386/1184 |
| 2019 | 37.54% 333/1092 |
26.57% 397/739 |
-0.19% 226/788 |
1.69% 372/850 |
7.06% 493/918 |
| 2018 | -22.96% 264/834 |
- - |
-8.82% 249/631 |
-0.95% 216/660 |
-11.93% 387/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方沪深300ETF联接C VS. 长安沪深300非周期A(740101) |